Latest Germany News

Rua Bioscience's FY26 results highlight a 71% surge in customer revenue driven by international expansion, yet the company continues to face significant losses and going concern risks.

Neuren Pharmaceuticals reported an 8% rise in H1 2026 revenues driven by DAYBUE royalties, but profit fell 68% due to ramped-up R&D. The company declared its first ever dividend, signalling confidence amid ongoing clinical and regulatory milestones.

Lovisa Holdings reported a robust FY26 with revenue up 17.6% to A$938.8 million, expanded its global store network to 1,136 locations, and declared a 33 cent final dividend, reflecting strong momentum in key markets.

Camplify Holdings slashed its net loss by 95% in FY26, posting a second-half profit driven by cost cuts and the MyWay Mutual insurance launch, setting a foundation for growth in FY27.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.

EVT Limited posted strong FY26 growth across hotels and entertainment, unveiling a $800 million capital recycling program and a strategic group structure review to fuel future expansion.

WAM Global's FY2026 investment portfolio fell 4.2%, dragging the company to a $35.2 million net loss despite a 6.6 cent fully franked final dividend.

Hansen Technologies posted a modest 1.5% revenue dip to $386.5 million in FY26 but delivered a 15.9% rise in underlying NPATA to $65.9 million, driven by recurring revenue growth and AI-enabled efficiencies. The company also announced a planned CEO succession to support its next growth phase.

Impact Minerals (ASX:IPT) has initiated a renounceable pro-rata entitlement offer to raise up to $4.13 million at $0.032 per share, with two free attaching options for every three new shares. The partially underwritten raise aims to fund exploration and development across its key projects including High Purity Alumina.

Life360 has surged past 100 million monthly active users, posting record revenue and subscriber growth in Q2 2026. Its AI-driven platform and expanding advertising business underpin strong profitability and a confident outlook.

Percheron Therapeutics announces Dr Michael Baker as incoming CEO, replacing Dr James Garner who steps down after three years. Baker’s appointment aligns executive incentives with shareholder value as the company prepares for a pivotal HMBD-002 clinical trial.

Viking Mines has uncovered significant tungsten mineralisation in historical rock stockpiles at its Linka Tungsten Project, Nevada, with assay results reaching 1.8% WO3, well above the historical mined average. The findings open the door to potential ore sorting applications and advance the project towards a brownfields restart.